Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
0(0%)
Results Posted
43%(6 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_4
8
53%
Ph phase_1
1
7%
Ph phase_3
5
33%

Phase Distribution

1

Early Stage

0

Mid Stage

13

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 3Large-scale testing
5(35.7%)
Phase 4Post-market surveillance
8(57.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.3%

14 of 15 finished

Non-Completion Rate

6.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(14)
Terminated(1)

Detailed Status

Completed14
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
93.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.1%)
Phase 35 (35.7%)
Phase 48 (57.1%)

Trials by Status

terminated17%
completed1493%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT06785090Phase 4

Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery

Completed
NCT05158699Phase 3

Effectiveness of Periocular Drug Injection in CATaract Surgery

Terminated
NCT04343222Phase 4

Control of Pain in Intravitreal Injections Using Topical NSAIDs

Completed
NCT01310127Phase 4

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Completed
NCT01535443Phase 1

Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.

Completed
NCT03886779Phase 4

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

Completed
NCT01774474Phase 3

PRevention of Macular EDema After Cataract Surgery

Completed
NCT01475877

Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy

Completed
NCT00198445Phase 3

Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery

Completed
NCT00423007Phase 3

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

Completed
NCT00704418Phase 3

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Completed
NCT00758199Phase 4

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

Completed
NCT01021761Phase 4

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

Completed
NCT00595543Phase 4

Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

Completed
NCT00520260Phase 4

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15